

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 4 mai 2023 11:46

Laboratory Information

Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:	Turkey rhinotracheitis (avian metapneumovirus infections)
Address of laboratory:	Anses, BP53, 41 rue de Beaucemaine, 22440 PLOUFRAGAN, FRANCE
Tel.:	+33296016222
E-mail address:	nicolas.etteradosi@anses.fr
Website:	https://www.anses.fr/en/content/ploufragan-plouzan%C3%A9-niort-laboratory
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nicolas ETERRADOSSI
Name (including Title and Position) of WOAHO Reference Expert:	Dr Nicolas ETERRADOSSI
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
ELISA for the detection of AMPV antibodies	yes	2459	0
Direct diagnostic tests		Nationally	Internationally
detection and quantification of			

AMPV genome by dd RT-qPCR	no	234	0
---------------------------	----	-----	---

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Inactivated antigen	ELISA	produced and provided	10 ml	0	1	Europe
Monospecific anti-sera	ELISA, VN, IIF	produced and provided	2 ml	0	1	Europe

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Yes

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
Five-Plex digital droplet PCR for the identification of the four AMPV subgroups (A, B, C and D)	Lemaitre E., Bougeard S., Allée C., Etteradossi N., Courtillon C., Brown P.A. (2022). Avian metapneumovirus: A five-plex digital droplet RT-PCR method for identification of subgroups A, B, C, and D. Front Vet Sci. 2022 Nov 15;9:1058294. doi: 10.3389/fvets.2022.1058294. eCollection 2022.

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

NAME OF THE WOA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
THE NETHERLANDS	Advice on use of molecular diagnostics for screening and sequencing vaccine and field strains of AMPV	Emails + telephone
POLAND	Advice on AMPV isolation from a case of swollen head syndrome in chickens	Emails + telephone
SPAIN	Advice on AMPV strains for experimental challenge studies	Emails + telephone

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Longitudinal Survey on aMPV Circulation in French Broiler Flocks following Different Vaccination Strategies	1 year	Evolution of AMPV-B in France	Department of Veterinary Medical Sciences, University of Bologna Department of Animal Medicine, Production and Health, University of Padua	

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Contribution to international study where samples from broiler flocks from 2017 to 2018 were collected in the West of France and analysed phylogenetically with historical French strains. This was published this year (Lupini et al., 2023 Animals)

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

3

Lupini C, Tucciarone CM, Mescolini G, Quaglia G, Graziosi G, Turblin V, et al. Longitudinal Survey on aMPV Circulation in French Broiler Flocks following Different Vaccination Strategies. *Animals*. 2023;13(1):57.

Kuhn JH, Adkins S, Alkhovsky SV, Avsic-Zupanc T, Ayllon MA, Bahl J, et al. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. *Arch Virol*. 2022. doi:10.1007/s00705-022-05546-z.

Lemaitre E., Bougeard S., Allée C., Etteradossi N., Courtillon C., Brown P.A. (2022). Avian metapneumovirus: A five-plex digital droplet RT-PCR method for identification of subgroups A, B, C, and D. *Front Vet Sci*. 2022 Nov 15;9:1058294. doi: 10.3389/fvets.2022.1058294. eCollection 2022.

b) International conferences:

1

Brown P. (2022) Avian Metapneumoviruses: What do we know? Key note lecture at the 10th International symposium on Avian Viral Respiratory Diseases Utrecht the Netherlands 21-24th June 2022

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

0

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	pdf	Compliance certificate ISO 17025 2023.pdf

19. Is your quality management system accredited?

No

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory quality management system and procedures comply with nationally applicable regulations and cover biorisk (biosafety and biosecurity) evaluation and management, in line with recommendations of chapter 1.1.4 of OIE Manual

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
Meetings of expert group for turkey rhinotracheitis	2022-01-01	online	contributor to several online meetings from Jan to May 2022	Contribution to the writing of turkey rhinotracheitis case definition

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Not applicable (only WOA Reference Laboratory designated for the disease)

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

Not applicable (Only WOA Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

Not applicable (Only WOA Reference Laboratory designated for the disease)

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Not applicable (Only WOA Reference Laboratory designated for the disease)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOA Member Countries
Antigen detection by ELISA	participant	26	Africa America Asia and Pacific Europe MiddleEast

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Participation in Expert group for turkey rhinotracheitis case definition	Online	See kind of consultancy

29. Additional comments regarding your report:

No